Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2015
ASCO 2015 Highlights
The Cost of Cancer Care: How Can We Spend Better?
By
Caroline Helwick
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
February 2012, Vol 3, No 1
San Antonio, TX—One of the few clinical science symposia at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium focused not on clinical issues but on delineating the economic issues facing oncologists.
Read Article
Bosutinib Shows Superior Results in CML
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Read Article
Ventura County Hematology Oncology Specialists: Efficiencies Crucial for Economic Viability
Best Practices
,
Policies & Guidelines
February 2012, Vol 3, No 1
Ventura County Hematology Oncology Specialists has so far managed to avoid many of the financial difficulties facing a large number of community cancer practices. Value-Based Cancer Care asked Dr Parsa and Ms Rivera to discuss what makes their practice successful from a clinical and a business perspective.
Read Article
Economic Implications of Biosimilars in Oncology
By
Caroline Helwick
Drug Updates
,
Biosimilars
December 2011, Vol 2, No 7
Alternative versions of biologic agents—biosimilars—will be coming soon to a formulary near you. In the meantime, many details must be worked out before patients can be safely and effectively treated with these new products.
Read Article
“Pediatric-Inspired” Regimens Improve Outcomes in Adults with ALL
By
Phoebe Starr
NCCN Conference
December 2011, Vol 2, No 7
Adults with acute lymphoblastic leukemia (ALL) have a poor prognosis compared with children, but recent studies suggest that using “pediatric-inspired” regimens can improve outcomes for patients with Philadelphia chromosome(Ph)- negative ALL.
Read Article
A New Paradigm of Value-Based Cancer Care: The NCCCP
By
Mark J. Krasna, MD
Cancer Care
,
Economics & Value
,
Value-Based Care
December 2011, Vol 2, No 7
Read Article
Ruxolitinib a New Oral Option for the Treatment of Patients with Intermediate- or High-Risk Myelofibrosis Disorders
By
Rhonda Williams
Cancer Drugs
,
Personalized Medicine
December 2011, Vol 2, No 7
Myeloproliferative neoplasms (MPNs) are a group of closely related hematologic malignancies that arise from abnormal development and function of the body’s bone marrow cells. Primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET) comprise the Philadel phia chromosome (Ph)-negative MPNs.
Read Article
Pathologists Can Play Key Role in the Era of Personalized Oncology
By
Rosemary Frei, MSc
American Pathologists Meeting
December 2011, Vol 2, No 7
The role of pathologists in gathering and interpreting oncologic information has never been as complex as it is today, but neither has it been as clinically impactful, suggested presenters at the 2011 College of American Pathologists meeting.
Read Article
AMA Calls for More Transparency in Patient Navigation Programs
By
Caroline Helwick
Patient Navigation
,
Policies & Guidelines
December 2011, Vol 2, No 7
The House of Delegates of the American Medical Association (AMA) laid out guidelines for patient navigator programs during their November 2011 Interim Meeting. The aim is to ensure that patient navigators “enhance, rather than undermine, the delivery of high-quality patient care,” the resolution states.
Read Article
Is Sentinel Lymph Node Biopsy Truly the Standard of Care in Melanoma?
By
Rosemary Frei, MSc
American Pathologists Meeting
December 2011, Vol 2, No 7
Two expert oncologists presented the clinical data in support for and against the use of sentinel lymph node biopsy (SLNB) in melanoma as the standard of care during the 2011 College of American Pathologists annual meeting.
Read Article
Page 301 of 330
298
299
300
301
302
303
304
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
ACCC Federal Policy Update Highlights Key Risks and Opportunities for Oncology Practices in 2026
Meg Barbor, MPH
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma